{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:42:47Z","timestamp":1792233767512,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.019","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:55:02Z","timestamp":1790783702000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Toxicities of Contemporary Cancer Immunotherapies: A Narrative Review of Immune Checkpoint Inhibitors, Bispecific T-Cell Engagers, and CAR-T Cell Therapies"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9428","authenticated-orcid":false,"given":"Jean","family":"El Cheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7446-4312","authenticated-orcid":false,"given":"Bahaa El Deen","family":"Wehbeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6477-5286","authenticated-orcid":false,"given":"Ali","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8968-7595","authenticated-orcid":false,"given":"Ralf","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgio","family":"Sayde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Charbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Kautaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan M.","family":"Refaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clml.2026.09.019_bib0001","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.clml.2026.09.019_bib0002","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"16","key":"10.1016\/j.clml.2026.09.019_bib0003","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clml.2026.09.019_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"11","key":"10.1016\/j.clml.2026.09.019_bib0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.clml.2026.09.019_bib0006","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2026.09.019_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.clml.2026.09.019_bib0008","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.09.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.clml.2026.09.019_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.37222","article-title":"Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: a meta-analysis","volume":"7","author":"Koeckerling","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.clml.2026.09.019_bib0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.09.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008518","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy","volume":"12","author":"Sayed","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clml.2026.09.019_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1677984","article-title":"Overview of immune checkpoint inhibitor associated myocarditis mechanisms diagnostics and treatment","volume":"16","author":"Feng","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clml.2026.09.019_bib0014","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clml.2026.09.019_bib0015","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/hc3401.095198","article-title":"Advances in the understanding of myocarditis","volume":"104","author":"Liu","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2026.09.019_bib0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.09.019_bib0017","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2512645","article-title":"A review of immune checkpoint inhibitor-associated myocarditis: epidemiology, pathogenesis, and biomarkers","volume":"21","author":"Xu","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.clml.2026.09.019_bib0018","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.immuni.2024.03.002","article-title":"DAMPs and DAMP-sensing receptors in inflammation and diseases","volume":"57","author":"Ma","year":"2024","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.clml.2026.09.019_bib0019","doi-asserted-by":"crossref","first-page":"H734","DOI":"10.1152\/ajpheart.00687.2024","article-title":"Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review","volume":"328","author":"Jensen","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"12","key":"10.1016\/j.clml.2026.09.019_bib0020","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.09.019_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad013","article-title":"Combination therapies for the optimisation of bispecific T-cell Engagers in cancer treatment","volume":"3","author":"Zhu","year":"2023","journal-title":"Immunother Adv"},{"issue":"24","key":"10.1016\/j.clml.2026.09.019_bib0022","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","article-title":"Cardiovascular toxicities associated with novel cellular immune therapies","volume":"8","author":"Munir","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.09.019_bib0023","doi-asserted-by":"crossref","first-page":"113","DOI":"10.36401\/JIPO-20-10","article-title":"Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias","volume":"3","author":"Simbaqueba","year":"2020","journal-title":"J Immunother Precis Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.019_bib0024","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"10.1016\/j.clml.2026.09.019_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1090103","article-title":"Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: a clinical appraisal","volume":"10","author":"Camilli","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.clml.2026.09.019_bib0026","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","article-title":"Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease","volume":"280","author":"Totzeck","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clml.2026.09.019_bib0027","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41569-026-01265-z","article-title":"Cardiotoxicity of T cell immunotherapies","volume":"23","author":"Raddatz","year":"2026","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.clml.2026.09.019_bib0028","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/ejh.14289","article-title":"The cardiotoxic effects of CAR-T cell therapy: an updated systematic review and meta-analysis","volume":"113","author":"Mazetto","year":"2024","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.09.019_bib0029","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.clml.2026.09.019_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.clml.2026.09.019_bib0031","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.clml.2026.09.019_bib0032","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.09.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-03391-z","article-title":"Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T\u202fcell engagers in multip myeloma","volume":"15","author":"Shan","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clml.2026.09.019_bib0034","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2026.09.019_bib0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.09.019_bib0036","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.clml.2026.09.019_bib0037","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.clml.2026.09.019_bib0038","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.clml.2026.09.019_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.clml.2026.09.019_bib0040","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2026.09.019_bib0041","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2026.09.019_bib0042","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.019_bib0043","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12471-022-01734-3","article-title":"Global longitudinal strain: an early marker for cardiotoxicity in patients treated for breast cancer","volume":"31","author":"van der Linde","year":"2023","journal-title":"Neth Heart J"},{"issue":"41","key":"10.1016\/j.clml.2026.09.019_bib0044","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.clml.2026.09.019_bib0045","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.clml.2026.09.019_bib0046","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ejh.70040","article-title":"Predictive factors and baseline risk stratification for CAR-T cell therapy-related cardiovascular toxicity","volume":"116","author":"Farmakis","year":"2026","journal-title":"Eur J Haematol"},{"issue":"20","key":"10.1016\/j.clml.2026.09.019_bib0047","first-page":"2452","article-title":"How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy","volume":"141","author":"Gutierrez","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2026.09.019_bib0048","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.09.019_bib0049","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.clml.2026.09.019_bib0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.clml.2026.09.019_bib0051","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.019_bib0052","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.clml.2026.09.019_bib0053","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.clml.2026.09.019_bib0054","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.clml.2026.09.019_bib0055","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.clml.2026.09.019_bib0056","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2026.09.019_bib0057","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.clml.2026.09.019_bib0058","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/blood.2019003618","article-title":"The earlier the better: timely mitigation of CRS","volume":"134","author":"Rouce","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.019_bib0059","doi-asserted-by":"crossref","first-page":"10318","DOI":"10.1182\/blood-2022-167688","article-title":"ZUMA-19: a phase 1\/2 study of Axicabtagene Ciloleucel plus Lenzilumab in patients with relapsed or refractory large B-cell lymphoma","volume":"140","author":"Oluwole","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.09.019_bib0060","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2026.09.019_bib0061","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.09.019_bib0062","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"42","key":"10.1016\/j.clml.2026.09.019_bib0063","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.clml.2026.09.019_bib0064","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","article-title":"Cardiovascular considerations before cancer therapy: gaps in evidence and JACC: cardioOncology expert panel recommendations","volume":"6","author":"Raisi-Estabragh","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.clml.2026.09.019_bib0065","doi-asserted-by":"crossref","first-page":"1809002","DOI":"10.3389\/fcvm.2026.1809002","article-title":"Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis","volume":"13","author":"El Cheikh","year":"2026","journal-title":"Front Cardiovasc Med"},{"issue":"21","key":"10.1016\/j.clml.2026.09.019_bib0066","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029574","article-title":"Circulating cardiovascular biomarkers in cancer therapeutics-related cardiotoxicity: review of critical challenges, solutions, and future directions","volume":"12","author":"Murtagh","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.clml.2026.09.019_bib0067","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026039832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026039832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:55:06Z","timestamp":1792230906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026039832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":67,"alternative-id":["S2152265026039832"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Toxicities of Contemporary Cancer Immunotherapies: A Narrative Review of Immune Checkpoint Inhibitors, Bispecific T-Cell Engagers, and CAR-T Cell Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}